Table 2.
Endpoint Analysis.
| Prasugrel group (n=250) |
Clopidogrel group (n=250) |
p value | ||
|---|---|---|---|---|
| Safety endpoints | ||||
| PCI-related bleeding | ||||
| Hemoglobin reduction: g/dL | 1.14±1.07 | 1.01±0.99 | 0.266 | |
| Hemoglobin reduction ≥3.0 g/dL: n (%) | 13 (5.2) | 11 (4.4) | 0.676 | |
| Additional hemostasis: n (%) | 29 (11.6) | 15 (6.0) | 0.027 | |
| Hematoma formation: n (%) | 16 (6.4) | 10 (4.0) | 0.243 | |
| Blood transfusion: n (%) | 5 (2.0) | 3 (1.2) | 0.475 | |
| Composite of PCI-related bleeding: n (%) | 56 (22.4) | 33 (13.2) | 0.007 | |
| Non-PCI-related bleeding | ||||
| TIMI major bleeding: n (%) | 1 (0.4) | 1 (0.4) | 1.000 | |
| TIMI minor bleeding: n (%) | 0 (0.0) | 0 (0.0) | 1.000 | |
| Clinically relevant minimal bleeding: n (%) | 6 (2.4) | 3 (1.2) | 0.312 | |
| Efficacy endpoint | ||||
| All-cause death: n (%) | 3 (1.2) | 0 (0.0) | 0.082 | |
| MACE: n (%) | 4 (1.6) | 8 (3.2) | 0.243 | |
| MACE+revascularization: (%) | 12 (4.0) | 26 (10.4) | 0.018 | |
| Heart failure requiring hospitalization: n (%) | 3 (1.2) | 5 (2.0) | 0.402 | |
PCI: percutaneous coronary intervention, TIMI: thrombolysis in myocardial infarction, MACE: major adverse cardiovascular events